About Us
Stelexis Therapeutics is committed to transforming cancer treatment through the discovery of novel targets aimed at the tumor’s origin. Pre-cancer and cancer stem cells (cancerous stem cells) are a primary cause of cancer progression and relapse, and they’re typically not eliminated by current treatment approaches. Previously, identifying targets on cancerous stem cells was almost impossible due to difficulties isolating, propagating and maintaining clinically relevant stem cells for research. Aided by seminal discoveries at leading academic institutions, the Company has developed a proprietary platform, called TumorOrigin™, which enables unprecedented study of these cells for drug discovery.